Nerivio is a wearable migraine treatment that stimulates the body’s pain receptors to relieve acute and chronic migraines.
Post Date – 01:00 PM, Wednesday – 1/11/23
Hyderabad: Israeli digital therapeutics company Theranica has announced a strategic licensing and supply agreement with Dr. Reddy’s Laboratories Ltd. to exclusively market and distribute its FDA-approved Nerivio in India following completion of the regulatory approval process.
Nerivio is a wearable migraine treatment that stimulates the body’s pain receptors to relieve acute and chronic migraines.
Under the terms of the agreement, Dr. Reddy will be responsible for Nerivio’s regulatory approval in India, after which it will exclusively market Nerivio in the country, manufactured and supplied by Theranica, according to a Theranica press release on Tuesday.
“This agreement fits perfectly with Theranica’s founders’ vision. The successful combination of Theranica’s neuroscience and digital health R&D with Dr. Reddy’s industry leadership and large commercial footprint will bring Nerivio to millions of people in need of effective migraine treatment — in India, and hopefully later in other parts of the world,” said Alon Ironi, CEO and Co-Founder of Theranica.
The agreement includes an exclusive license fee to sell Nerivio in India. The press release added that while the agreement applies only to India, the two companies will continue to discuss expanding their business beyond the US and China.
